Entering a far more interesting phase than chart first suggest!Cereno Scientific AB Class BOMXSTO_DLY:CRNO_BTrueessence31Cereno Scientific is entering a far more interesting phase now than the chart alone first suggests. After a full year of selling pressure from the 11.90 SEK peak down to the 4.30 SEK low, the stock is no longer just trying to stabilise — it is entering a catalyst-heavy window at the same time as the technical structure is tightening into its main decision zone. That is what makes the setup interesting here. Several things are starting to line up at roughly the same time: momentum is improving, volume is picking up, the daily chart is trying to reclaim higher structure, and the company is moving into one of its most important catalyst periods in a long time. CS1 Phase IIb initiation, 15-month EAP data, CS014 PK bridging data and the broader financing/partnering backdrop are all landing while the chart is compressing between a long-term descending trendline and a rising trendline from the 4.30 low. This is still an early-stage medtech/biotech chart, which means the daily timeframe leads while the weekly structure is trying to catch up behind it. But that is also why the current setup matters: if the stock confirms above 6.20 SEK, it does not just break a local range — it starts moving out of a compression pattern that has been building for months right as the fundamental news flow is turning materially more relevant. The setup is defined by two converging trendlines: a long-term descending trendline from 11.90 SEK and a rising trendline from the 4.30 SEK low. Price is being squeezed between them, volatility is dropping, and momentum is improving. This is the type of structure where the next move tends to be decisive. The key level where the chart flips from consolidation to expansion is 6.20 SEK. Momentum & RSI: Daily RSI (9) is around 61.8, confirming a momentum shift. Weekly RSI is still neutral at 45–50 but improving. Daily RSI above 61 is confirmed; weekly RSI above 60 is the structural confirmation still pending. Moving averages: Daily SMA50 reclaim is in progress. EMA 5/9 crossover EMA20 is pending. All candles must close above 6.20 SEK for confirmation. On the weekly chart, price must reclaim EMA20, EMA9 must separate upward, and weekly RSI must close above 55–60. Key levels: Support: 4.70 (June low), 5.20 (execution stop), 5.776 (recent structure). Confirmation: 6.20 SEK. Targets: 8.0, 10.34, 12.0 SEK. Above 10.34 SEK, the financing facility unlocks fully, which is both a technical and fundamental trigger. Fundamentals: Edison’s June 2026 update highlights several value-inflection events: – CS1 Phase IIb initiation (June 2026) – 15-month EAP efficacy data (June 2026) – CS014 PK bridging data (mid-2026) – APS selected as lead indication for CS585 – Partnering discussions accelerating – Valuation raised to 21.7 SEK/share The company has a 650 MSEK financing facility, but full access requires the share price to reach 10.34 SEK, which aligns with the technical structure. Trade logic: Position: 25,000 shares at 5.93 SEK. Add 25,000 more only if: – All candles close above 6.20 – Weekly EMA20 reclaim – Weekly RSI > 60 – Daily RSI > 61 – Daily SMA50 reclaim – EMA 5/9 crossover EMA20 Stops: 5.20 SEK (execution), 4.70 SEK (structural). Targets: 8.0 → 10.34 → 12.0 SEK. Core thesis: CRNO.B is forming a clean compression pattern where a long-term descending trendline meets a rising short-term trendline. Momentum is improving, volume is picking up, and the stock is entering a catalyst-dense period. This is not a “cheap stock” setup — it’s a trendline convergence + momentum shift case with a clear confirmation level at 6.20 SEK. The opportunity is not in guessing but in waiting for the structure to prove itself.